Vir Biotechnology Stock Cash And Equivalents
| VIR Stock | USD 7.96 0.10 1.27% |
Vir Biotechnology fundamentals help investors to digest information that contributes to Vir Biotechnology's financial success or failures. It also enables traders to predict the movement of Vir Stock. The fundamental analysis module provides a way to measure Vir Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vir Biotechnology stock.
Vir | Cash And Equivalents |
Vir Biotechnology Company Cash And Equivalents Analysis
Vir Biotechnology's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Vir Biotechnology Cash And Equivalents | 2.2 B |
Most of Vir Biotechnology's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vir Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vir Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Vir Biotechnology is extremely important. It helps to project a fair market value of Vir Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Vir Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vir Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vir Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Vir Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Vir Biotechnology has 2.2 B in Cash And Equivalents. This is 168.01% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 18.58% higher than that of the company.
Vir Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vir Biotechnology's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vir Biotechnology could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics of similar companies.Vir Biotechnology is currently under evaluation in cash and equivalents category among its peers.
Vir Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vir Biotechnology from analyzing Vir Biotechnology's financial statements. These drivers represent accounts that assess Vir Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vir Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 3.2B | 5.4B | 3.4B | 1.3B | 2.0B | |
| Enterprise Value | 1.2B | 2.8B | 5.2B | 2.6B | 1.2B | 1.8B |
Vir Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vir Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vir Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Vir Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (91.85) % | ||||
| Current Valuation | 294.59 M | ||||
| Shares Outstanding | 137.72 M | ||||
| Shares Owned By Insiders | 11.90 % | ||||
| Shares Owned By Institutions | 74.45 % | ||||
| Number Of Shares Shorted | 5.51 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 0.88 X | ||||
| Price To Sales | 13.94 X | ||||
| Revenue | 86.18 M | ||||
| Gross Profit | 1.03 B | ||||
| EBITDA | (664.85 M) | ||||
| Net Income | (615.06 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 124.54 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 9.08 X | ||||
| Cash Flow From Operations | (778.78 M) | ||||
| Short Ratio | 4.36 X | ||||
| Earnings Per Share | (3.93) X | ||||
| Price To Earnings To Growth | 1.14 X | ||||
| Target Price | 29.5 | ||||
| Number Of Employees | 587 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 1.92 B | ||||
| Retained Earnings | (237.82 M) | ||||
| Working Capital | 1.41 B | ||||
| Net Asset | 1.92 B |
About Vir Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vir Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vir Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vir Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Vir Stock
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.